Category Archives: Uncategorized

BALA CYNWYD, Pa., Aug. 3, 2017 — Chondrial Therapeutics, Inc., an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lead investigational drug candidate, CTI-1601, being developed for the treatment of Friedreich’s Ataxia. Orphan drug designation is granted […]

Company Plans to Advance Pipeline of Product Candidates Focused on the Treatment of Rare Mitochondrial Diseases Carole Ben-Maimon, MD, Named President & CEO Bala Cynwyd, PA – January 31, 2017 – Chondrial Therapeutics, Inc., an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced today that it has secured up […]